secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001438533-26-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere reports record Q4 FILSPARI sales of $103M; FSGS PDUFA decision due Jan 13
--------------------------------------------------------------------------------

- Preliminary Q4 2025 total U.S. net product sales ~$127M; FILSPARI sales ~$103M (+108% YoY).
- FY2025 total U.S. net product sales ~$410M; FILSPARI full-year sales ~$322M.
- Cash, equivalents and marketable securities ~$323M at year-end 2025.
- FSGS sNDA PDUFA target date Jan 13, 2026; responses to FDA's info requests submitted and under review.
- Pegtibatinase Phase 3 HARMONY study to restart in Q1 2026 after manufacturing optimization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/0001438533-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/tvtx-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer